

Vasculitis - Pipeline Insight, 2021

<https://marketpublishers.com/r/V83FFD50767EN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: V83FFD50767EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Vasculitis - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Vasculitis Understanding

Vasculitis: Overview

Vasculitis is an autoimmune disease that causes inflammation and narrowing of blood vessels (arteries, veins and capillaries). These vessels carry blood to and from the heart and the body's organs. Vasculitis occurs when the immune system mistakenly sees blood vessels as a foreign invader and attacks them. What causes this to happen isn't fully understood. These conditions can occur by themselves or with other rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE/ lupus) or Sjogrens syndrome. Other possible triggers include an infection (hepatitis B or C) or a medication side effect. Vasculitis also may be linked to certain blood cancers, such as leukemia and lymphoma.

'Vasculitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Vasculitis pipeline landscape is provided which includes the disease overview and Vasculitis treatment guidelines. The assessment part of the report embraces, in depth Vasculitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D. The therapies under development are focused on novel approaches to treat/improve Vasculitis.

Vasculitis Emerging Drugs Chapters

This segment of the Vasculitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vasculitis Emerging Drugs

Avacopan : ChemoCentryx

Avacopan is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis and other complement-driven autoimmune and inflammatory diseases. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA-associated vasculitis. The drug is in preregistration stage for the treatment of Anti-neutrophil cytoplasmic antibody-associated vasculitis.

Belimumab (Benlysta): GlaxoSmithKline

Benlysta, a BLyS-specific inhibitor, is a human monoclonal antibody that binds to soluble BLyS. Benlysta does not bind B cells directly. By binding BLyS, Benlysta inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. The drug is in phase 3 of clinical trials for the treatment of Anti-neutrophil cytoplasmic antibody-associated vasculitis.

Tocilizumab (Actemra): Roche

Actemra (tocilizumab) is a humanized anti IL-6 receptor monoclonal antibody and binds specifically to IL-6 receptors. IL-6 is a pro-inflammatory cytokine. The drug is registered for the treatment of vasculitis.

Further product details are provided in the report.....

Vasculitis: Therapeutic Assessment

This segment of the report provides insights about the different Vasculitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Vasculitis

There are approx. 10+ key companies which are developing the therapies for Vasculitis. The companies which have their Vasculitis drug candidates in the most advanced stage, i.e. preregistration include, ChemoCentryx

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vasculitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vasculitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasculitis drugs.

Vasculitis Report Insights

- Vasculitis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Vasculitis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Vasculitis drugs?

How many Vasculitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vasculitis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vasculitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Vasculitis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

ChemoCentryx

GlaxoSmithKline

Roche

AbbVie

InflaRx

CytoDyn

Toleranzia

Citryll

Levolta

Key Products

Avacopan

Belimumab (Benlysta)

Tocilizumab (Actemra)

Upadacitinib

Vilobelimab (IFX-1)

Leronlimab

TOL3

CIT 013

Contents

- Introduction
- Executive Summary
- Vasculitis: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Vasculitis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Vasculitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Vasculitis Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Preregistration)
 - Comparative Analysis
- Avacopan: ChemoCentryx
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Vilobelimab: InflaRx
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

Preclinical and Discovery stage
 Comparative Analysis
CIT 013: Citryll
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Vasculitis Key Companies
Vasculitis Key Products
Vasculitis- Unmet Needs
Vasculitis- Market Drivers and Barriers
Vasculitis- Future Perspectives and Conclusion
Vasculitis Analyst Views
Vasculitis Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Vasculitis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Vasculitis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Vasculitis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/V83FFD50767EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V83FFD50767EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970